SPOTLIGHT: India emerging as big drug market


Indian pharma companies have had to weather a series of big changes in recent times, including big pharma's successful strategy in aggressively challenging generics. But the Wall Street Journal's trend piece also notes that over the next decade Indians' appetite for drugs will grow from $8 billion to $30 billion, making it an important market for the drug companies. Report

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.